with pharmacological treatment

The MET-FINGER trial is an international, randomized clinical trial, based on the ground-breaking  FINGER study. For the first time, a lifestyle-based intervention (the FINGER model) will be tested in association with pharmacological treatment, metformin, with the aim of preventing cognitive impairment and dementia.

Conducted across three sites in the UK, Finland, and Sweden, the trial will include a total of 600 participants aged 60-79 years with increased risk of developing dementia, but with no current memory problems or dementia diagnoses.

Metformin is an approved drug and the first line pharmacological treatment for type 2 diabetes. It may help prevent dementia and cognitive decline by controlling high blood glucose levels, a well-known risk factor for dementia. Due to its novel design and approach, the trial’s findings will be key for the development, world-wide, of a new generation of clinical trials combining lifestyle interventions and medications.

The project started in 2023.

A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol

Swedish MET-FINGER study team during baseline visits.